About Ovid Therapeutics Inc.
https://www.ovidrx.comOvid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.
CEO
Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
TAKEDA PHARMACEUTICAL CO LTD
Shares:7.53M
Value:$12.43M
BLACKROCK INC.
Shares:3.99M
Value:$6.59M
VANGUARD GROUP INC
Shares:2.82M
Value:$4.65M
Summary
Showing Top 3 of 94
About Ovid Therapeutics Inc.
https://www.ovidrx.comOvid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $132K ▼ | $12.64M ▲ | $-12.16M ▼ | -9.21K% ▼ | $-0.17 ▼ | $-12.14M ▼ |
| Q2-2025 | $6.27M ▲ | $11.35M ▼ | $-4.68M ▲ | -74.68% ▲ | $-0.07 ▲ | $-4.97M ▲ |
| Q1-2025 | $130K ▲ | $12.68M ▲ | $-10.23M ▼ | -7.87K% ▲ | $-0.14 ▼ | $-12.41M ▼ |
| Q4-2024 | $76K ▼ | $10.8M ▼ | $-9.25M ▲ | -12.18K% ▼ | $-0.13 ▲ | $-10.76M ▲ |
| Q3-2024 | $173K | $13.4M | $-14.01M | -8.1K% | $-0.2 | $-13.06M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $25.6M ▼ | $63.85M ▼ | $19.15M ▼ | $44.7M ▼ |
| Q2-2025 | $38.35M ▼ | $77.43M ▼ | $21.64M ▼ | $55.79M ▼ |
| Q1-2025 | $43M ▼ | $81.65M ▼ | $22.38M ▼ | $59.28M ▼ |
| Q4-2024 | $53.08M ▼ | $92.17M ▼ | $23.94M ▼ | $68.23M ▼ |
| Q3-2024 | $62.71M | $102.65M | $26.36M | $76.29M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-12.16M ▼ | $-12.87M ▼ | $5.05M ▼ | $15K ▲ | $-7.8M ▼ | $-12.87M ▼ |
| Q2-2025 | $-4.68M ▲ | $-4.77M ▲ | $12.05M ▲ | $0 ▼ | $7.28M ▲ | $-4.77M ▲ |
| Q1-2025 | $-10.23M ▼ | $-10.28M ▼ | $5.1M ▼ | $13K ▲ | $-5.17M ▼ | $-10.28M ▼ |
| Q4-2024 | $-9.25M ▲ | $-10.01M ▲ | $21.29M ▲ | $0 ▼ | $11.28M ▲ | $-10.03M ▲ |
| Q3-2024 | $-14.01M | $-15.01M | $292K | $38K | $-14.68M | $-15M |
Revenue by Products
| Product | Q4-2022 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Reportable Segment | $0 ▲ | $0 ▲ | $10.00M ▲ | $0 ▼ |
 License | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
TAKEDA PHARMACEUTICAL CO LTD
Shares:7.53M
Value:$12.43M
BLACKROCK INC.
Shares:3.99M
Value:$6.59M
VANGUARD GROUP INC
Shares:2.82M
Value:$4.65M
Summary
Showing Top 3 of 94